Brain cancer vaccine shows promise in early trial

NCT ID NCT02455557

Ongoing Disease control Sponsor: Roswell Park Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This phase II study tests a vaccine called SurVaxM, designed to train the immune system to attack glioblastoma cells, when given alongside standard chemotherapy (temozolomide). The trial includes 66 patients with newly diagnosed, survivin-positive glioblastoma or gliosarcoma. The main goal is to see how many patients are alive without tumor progression six months after diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SVN53-67/M57-KLH Peptide Vaccine (SurVaxM) combined with temozolomide chemotherapy
What this could lead to: If it works, this could offer a new way to extend the time glioblastoma patients live without their tumor growing.
What could go wrong: This is a small, early-phase trial (66 people) with no control group, so results may not prove the vaccine works. Glioblastoma is very aggressive, and many promising treatments have failed before.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1 gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOSARCOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Cleveland, Ohio, 44195, United States
Dana-Farber Harvard Cancer Center

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States
Roswell Park Cancer Institute

Buffalo, New York, 14263, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.